Humacyte sets out to bring regenerative medicine to Wall Street, then the world February 18, 2021 Auto Bot BioPharma, biopharma nl, Durham, hospitals, North Carolina, Pharma, regenerative medicine 0 Humacyte is going public via a SPAC merger that infuses it with $255 million for its regenerative medicine pipeline. The biotech’s technology produces universally implantable tissue that functions like human blood vessels.